Aptus Pharma

Why is Aptus Pharma Ltd falling/rising?

As of 10-Aug, Aptus Pharma Ltd's stock price is at 274.25, down 1.98% and has lost 7.72% over the last four days. Investor participation has decreased significantly, indicating reduced interest, while the stock remains above longer-term moving averages but below the 5-day average, suggesting short-term weakness.

As of 10-Aug, Aptus Pharma Ltd's stock price is falling, currently at 274.25, which reflects a decrease of 5.55 or 1.98%. The stock has been underperforming, having lost 7.72% over the last four days, indicating a consecutive decline. Additionally, the stock's performance today has underperformed the sector by 1.72%. <BR><BR>Investor participation has also decreased significantly, with delivery volume dropping by 76.49% compared to the 5-day average, suggesting reduced interest from investors. Although the stock remains above its 20-day, 50-day, 100-day, and 200-day moving averages, it is below the 5-day moving average, which may indicate a short-term weakness. Overall, these factors contribute to the stock's current downward trend.

Which are the latest news on Aptus Pharma?

What does Aptus Pharma do?

Aptus Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 394 Cr. It has no reported net sales or profit for the latest quarter, a P/E ratio of 84.00, and a return on equity of 21.29%.

Overview:<BR>Aptus Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Details regarding the incorporation year and any status changes are not available. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 394 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 84.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.28<BR>Return on Equity: 21.29%<BR>Price-to-Book: 18.14<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Aptus Pharma?

Aptus Pharma's peers include Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, Valiant Laborato, Medico Remedies, Transchem, Medicamen Biotec, and Infinium Pharma. Key insights show Bafna Pharma has the highest 1-year return at 135.40%, while Medicamen Biotec has the lowest at -46.53%.

Peers: The peers of Aptus Pharma are Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, Valiant Laborato, Medico Remedies, Transchem, Medicamen Biotec, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jenburkt Pharma and Medico Remedies, while Average management risk is found at Haleos Labs Limi, Albert David, Transchem, and Medicamen Biotec, and the rest have Below Average management risk. Growth is Good at Valiant Laborato, while Below Average growth is seen at Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, Medico Remedies, Transchem, Medicamen Biotec, and Infinium Pharma. Excellent capital structure is noted at Jenburkt Pharma, Albert David, and Medicamen Biotec, while Good capital structure is seen at Bafna Pharma and Medico Remedies, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma at 135.40%, while Medicamen Biotec has the lowest at -46.53%. Aptus Pharma's 1-year return is not available for comparison. Additionally, peers with negative six-month returns include Haleos Labs Limi, Albert David, Valiant Laborato, Medico Remedies, and Medicamen Biotec.

What is the bonus history of Aptus Pharma?

Aptus Pharma recently announced a 3:2 bonus issue, with an ex-date of May 12, 2026. Shareholders on record by this date will receive 3 additional shares for every 2 shares they currently hold.

Aptus Pharma has a recent bonus issue where they announced a 3:2 bonus. The ex-date for this bonus is set for May 12, 2026. This means that shareholders on record as of this date will receive additional shares in the ratio of 3 shares for every 2 shares they currently hold.